Table 3 Patient-level factors associated with receiving low-dose dabigatran from the Veterans Health Administration, as compared to receiving full-dose, among those who met clinical criteria to receive full-dose dabigatran for non-valvular atrial fibrillation (n = 26,146)

 ≤ 69

18.0%

55.7%

REF

 70–74

10.4%

20.5%

1.43

(0.98, 2.06)

0.06

 75–79

9.5%

10.8%

1.81

(1.20, 2.69)

0.004

 >  80

62.0%

12.9%

6.41

(4.68, 8.84)

<  0.001

 Female

2.7%

1.6%

1.38

(0.68, 2.55)

0.34

 Male

97.3%

98.4%

REF

 White

85.3%

86.6%

REF

 Black

7.7%

7.2%

1.28

(0.86, 1.87)

0.21

 Other

7.1%

6.2%

1.06

(0.68, 1.59)

0.80

 Northeast

12.0%

12.7%

REF

 Midwest

21.4%

23.9%

1.19

(0.83, 1.72)

0.34

 West

21.0%

23.8%

1.25

(0.88, 1.81)

0.22

 South

45.6%

39.6%

1.59

(1.16, 2.21)

0.004

 <  25

28.4%

14.6%

REF

 25–29.9

35.7%

30.6%

1.32

(1.02, 1.73)

0.04

 30–34.9

21.4%

27.5%

1.80

(1.31, 2.46)

<  0.001

 ≥ 35

11.2%

25.8%

1.52

(1.02, 2.26)

0.04

 Heart Failure

20.3%

13.6%

1.36

(1.03, 1.79)

0.03

 Hypertension

77.8%

71.6%

1.09

(0.83, 1.44)

0.55

 Vascular Disease

15.4%

13.2%

1.15

(0.86, 1.53)

0.34

 Diabetes

44.2%

41.4%

1.24

(0.98, 1.57)

0.07

 Prior Bleeding

4.6%

3.1%

1.20

(0.73, 1.90)

0.45

 Stroke

8.3%

5.9%

1.04

(0.71, 1.47)

0.85

 30–39

28.0%

1.9%

18.16

(13.05, 25.27)

<  0.001

 40–49

23.7%

4.6%

6.96

(5.05, 9.58)

<  0.001

 50–59

17.4%

7.9%

3.36

(2.42, 4.64)

<  0.001

 >  60

30.9%

85.6%

REF

 0–2

25.9%

30.0%

REF

 3–4

34.6%

39.1%

0.94

(0.71, 1.26)

0.69

 ≥ 5

30.5%

25.1%

1.35

(0.95, 1.91)

0.10